These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35163685)

  • 1. Developing a Mathematical Model of Intracellular Calcium Dynamics for Evaluating Combined Anticancer Effects of Afatinib and RP4010 in Esophageal Cancer.
    Chang Y; Funk M; Roy S; Stephenson E; Choi S; Kojouharov HV; Chen B; Pan Z
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma.
    Cui C; Chang Y; Zhang X; Choi S; Tran H; Penmetsa KV; Viswanadha S; Fu L; Pan Z
    Cancer Lett; 2018 Sep; 432():169-179. PubMed ID: 29908962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis.
    Dai CH; Zhu LR; Wang Y; Tang XP; Du YJ; Chen YC; Li J
    J Cell Physiol; 2021 Jun; 236(6):4538-4554. PubMed ID: 33230821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma.
    Yang LY; Cheng ZJ; Liu Z; Wang D; Zhang N; Fan ZL; Cai HQ; Zhang Y; Cai Y; Xu X; Wang JH; Du GH; Hao JJ; Wang MR
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2513-2522. PubMed ID: 33721913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma.
    Wang Y; Liu C; Chen H; Jiao X; Wang Y; Cao Y; Li J; Zhang X; Sun Y; Zhuo N; Dong F; Gao M; Wang F; Dong L; Gong J; Sun T; Zhu W; Zhang H; Shen L; Lu Z
    Signal Transduct Target Ther; 2024 Jun; 9(1):153. PubMed ID: 38937446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibitory effects of zinc on cell proliferation in esophageal squamous cell carcinoma through Orai1.
    Choi S; Cui C; Luo Y; Kim SH; Ko JK; Huo X; Ma J; Fu LW; Souza RF; Korichneva I; Pan Z
    FASEB J; 2018 Jan; 32(1):404-416. PubMed ID: 28928244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethacrynic Acid Enhances the Antitumor Effects of Afatinib in EGFR/T790M-Mutated NSCLC by Inhibiting WNT/Beta-Catenin Pathway Activation.
    Zhang X; Huang C; Cui B; Pang Y; Liang R; Luo X
    Dis Markers; 2021; 2021():5530673. PubMed ID: 34122668
    [No Abstract]   [Full Text] [Related]  

  • 8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
    Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
    Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways.
    Liu Z; Fu Q; Wang Y; Cui L; Zhang W; Teng Y; Yu P
    Biomed Pharmacother; 2021 Feb; 134():111144. PubMed ID: 33360044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
    Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
    Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance.
    Liu Z; Chen Z; Wang J; Zhang M; Li Z; Wang S; Dong B; Zhang C; Gao J; Shen L
    J Hematol Oncol; 2018 Aug; 11(1):109. PubMed ID: 30157900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Ninomiya T; Nogami N; Kozuki T; Harada D; Kubo T; Ohashi K; Kuyama S; Kudo K; Bessho A; Fukamatsu N; Fujimoto N; Aoe K; Shibayama T; Sugimoto K; Takigawa N; Hotta K; Kiura K
    Lung Cancer; 2018 Jan; 115():103-108. PubMed ID: 29290249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S; Shih JY; Jang TW; Liam CK; Yu Y
    Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial.
    Kobayashi N; Hashimoto H; Kamimaki C; Nagasawa R; Tanaka K; Kubo S; Katakura S; Chen H; Hirama N; Ushio R; Aoki A; Nakashima K; Teranishi S; Manabe S; Watanabe H; Horita N; Watanabe K; Hara Y; Yamamoto M; Kudo M; Piao H; Kaneko T
    Thorac Cancer; 2020 Aug; 11(8):2125-2129. PubMed ID: 32495514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma.
    Hong MH; Heo SG; Lee YG; Kim HS; Park KU; Kim HG; Ko YH; Chung IJ; Min YJ; Kim MK; Kim KR; Yoo J; Kim TM; Kim HR; Cho BC
    Cancer; 2020 Oct; 126(20):4521-4531. PubMed ID: 32749686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
    Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
    PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
    Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
    J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab.
    Oashi A; Yasuda H; Kobayashi K; Tani T; Hamamoto J; Masuzawa K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
    Mol Cancer Ther; 2019 Sep; 18(9):1593-1601. PubMed ID: 31253648
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.